Combining a peptide vaccine with high-dose interleukin-2

Journal of Clinical Oncology

Volumn 26, Issue 14, 2008, Pages 2250-2251

  Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; INTERLEUKIN 2; CANCER VACCINE; SUBUNIT VACCINE;

ANTINEOPLASTIC ACTIVITY; DRUG EFFECT; EDITORIAL; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG METASTASIS; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; DOSE RESPONSE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NOTE;

CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MELANOMA; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 44249104483     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7826     Document Type: Editorial

References (12)

1. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
2. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
3. Rosenberg S, Lotze M, Yang J, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484, 1989
4. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
5. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
6. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
7. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report. N Engl J Med 319:1676-1680, 1988
8. Dutcher J, Creekmore S, Weiss G, et al: A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477-485, 1989
9. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
10. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
11. Sosman JA, Carrillo C, Urba WJ, et al: Three phase II Cytokine Working Group trials of gp100 (210M) peptide plus high-dose interleukin-2 in HLA-A2-positive advanced melanoma patients. J Clin Oncol 26:2292-2298, 2008
12. Ahmadzadeh M, Rosenberg SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409-2414, 2006